Clinical trials: CTLA4
Wegener's Granulomatosis
Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis
Wegener's granulomatosis (WG) is a rare disease that causes inflammation of blood vessels, or vasculitis. It may involve many different parts of the body, but typically affects the upper and lower respiratory tract and kidneys.
- Trial name
- NCT00468208
- Testing
- Abatacept
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Pennsylvania
Pancreatic Neoplasms, Pancreatic Cancer
Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer
Background: Stereotactic body radiation therapy (SBRT) is used to treat cancer. It is a way of giving very focused beams of radiation to tumors.
- Conditions
- Pancreatic Neoplasms, Pancreatic Cancer, Cancer of Pancreas, Cancer of the Pancreas
- Trial name
- NCT02311361
- Testing
- Durvalumab, Tremelimumab, Sterostatic body radiation therapy (SBRT)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Unresectable or Metastatic Melanoma
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
The purpose of the study is to estimate the response rate and compare overall survival of patients taking BMS-936558 to those taking study physician's choice of either Dacarbazine or Carboplatin and Paclitaxel
- Trial name
- NCT01721746
- Testing
- BMS-936558, Dacarbazine, Carboplatin
- Where
- 95 sites in United States, Austria and 12 more
- Volunteers
- 405 people
- Sponsor
- Bristol-Myers Squibb
Cancer
JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors
JTX-2011-101 is a Phase 1/2, open label, dose escalation and expansion clinical study of JTX-2011 alone and in combination with nivolumab, ipilimumab, or pembrolizumab in adult subjects with advanced and/or refractory solid…
- Trial name
- ICONIC (NCT02904226)
- Testing
- JTX-2011, Nivolumab, Ipilimumab
- Where
- 16 sites in United States
- Volunteers
- 242 people
- Sponsor
- Jounce Therapeutics, Inc.
Advanced Cancer, Melanoma
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
The purpose of the study is to determine safety and effectiveness of experimental medication BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and Ipilimumab in patients with cancers that are advanced…
- Conditions
- Advanced Cancer, Melanoma, Non-Small Cell Lung Cancer
- Trial name
- NCT02658890
- Testing
- BMS-986205, Nivolumab, Ipilimumab
- Where
- 47 sites in United States, Australia and 9 more
- Volunteers
- 627 people
- Sponsor
- Bristol-Myers Squibb
Advanced Hepatocellular Carcinoma
Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)
The purpose of this study is to evaluate the safety and efficacy of fixed dose coformulated pembrolizumab/quavonlimab (MK-1308A) plus lenvatinib in a first line (1L) hepatocellular carcinoma (HCC) setting.
- Trial name
- NCT04740307
- Testing
- Pembrolizumab/Quavonlimab, Lenvatinib, Pembrolizumab
- Where
- 40 sites in United States, China and 7 more
- Volunteers
- 116 people
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma
CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma
The purpose of this study is to see whether the combination of low-dose Cyclophosphamide and Anti-CTLA4 (Ipilimumab) will stop tumor growth in patients with advanced skin cancer.
- Trial name
- NCT01740401
- Testing
- Cyclophosphamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Synovial Sarcoma
A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma
The purpose of this study is to determine whether immune therapy with anti-CTLA-4 antibody is effective in people with advanced synovial sarcoma.
- Trial name
- NCT00140855
- Testing
- ipilimumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Ludwig Institute for Cancer Research
Pancreatic Cancer
Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer
Research Hypothesis: Ipilimumab (an antibody that blocks negative signals to T cells) administered alone or in combination with a pancreatic cancer vaccine (allogeneic pancreatic tumor cells transfected with a GM-CSF gene), has…
- Trial name
- NCT00836407
- Testing
- Ipilimumab, Pancreatic Cancer Vaccine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Head and Neck Cancer
Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients
This is a non-randomized, open-label, Phase Ib study to assess the safety and efficacy of a DNA methyltransferase inhibitor and immune checkpoint inhibitor(s) (durvalumab and/or tremelimumab) combination therapy in the treatment…
- Trial name
- NCT03019003
- Testing
- Oral Decitabine, Durvalumab, 5' Azacitidine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Massachusetts General Hospital
Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
This phase I trial studies the side effects and best dose of blinatumomab when given with nivolumab alone or nivolumab and ipilimumab in treating patients with poor-risk CD19+ precursor B-lymphoblastic leukemia that has come back…
- Conditions
- Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Mixed Phenotype Acute Leukemia
- Trial name
- NCT02879695
- Testing
- Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy
- Where
- 7 sites in United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant
This was a Phase 1, open-label, multicenter, study of checkpoint inhibitor therapy (tremelimumab ± durvalumab) prior to and following autologous stem cell transplant (ASCT) and high-dose melphalan in subjects with multiple…
- Trial name
- NCT02716805
- Testing
- Tremelimumab, Durvalumab, Prevnar-13
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Ludwig Institute for Cancer Research
Solid Tumor, Lymphoma
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered intravenously (IV) as a single agent or in…
- Trial name
- NCT03013491
- Testing
- CX-072, ipilimumab, vemurafenib
- Where
- 31 sites in United States, Netherlands and 4 more
- Volunteers
- 196 people
- Sponsor
- CytomX Therapeutics
Advanced Malignant Solid Neoplasm, Anal Carcinoma
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of nivolumab when given with ipilimumab in treating patients with human immunodeficiency virus (HIV) associated classical Hodgkin lymphoma that has returned after a period…
- Conditions
- Advanced Malignant Solid Neoplasm, Anal Carcinoma, HIV Infection, Kaposi Sarcoma
- Trial name
- NCT02408861
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography
- Where
- 34 sites in United States, Australia
- Volunteers
- 79 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma of the Head and Neck
Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
In this Phase II trial of personalized immunotherapy in R/M HNSCC, gene expression of LAG3 and CTLA4 by RNA seq will be determined to select the appropriate agent (Ipilimumab or Relatlimab) to add to Nivolumab in patients with…
- Trial name
- NCT04326257
- Testing
- Nivolumab+Relatlimab, Nivolumab+Ipilimumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dan Zandberg
Heptocellular Cancer, Biliary Tract Neoplasms
Tremelimumab With Chemoembolization or Ablation for Liver Cancer
Background: Tremelimumab is a cancer treatment drug that helps the immune system recognize and destroy cancer cells. Researchers want to see if it can be used to treat advanced liver cancer.
- Conditions
- Heptocellular Cancer, Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma
- Trial name
- NCT01853618
- Testing
- Tremelimumab, RFA, TACE
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Non-Small Cell Lung Carcinoma
A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer
The primary objective of the study is to compare the objective response rate (ORR) of high dose cemiplimab (HDREGN2810) and standard dose cemiplimab plus ipilimumab combination therapy (SDREGN2810/ipi) to the ORR of standard dose…
- Trial name
- NCT03430063
- Testing
- SDREGN2810, SDREGN2810/ipi, HDREGN2810
- Where
- 31 sites in United States, Belgium and 7 more
- Volunteers
- 28 people
- Sponsor
- Regeneron Pharmaceuticals
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy
This phase II trial studies how well abatacept, ixazomib citrate, and dexamethasone work in treating patients with multiple myeloma that is resistant to chemotherapy.
- Trial name
- NCT03457142
- Testing
- Abatacept, Dexamethasone, Ixazomib Citrate
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Roswell Park Cancer Institute
Intermediate Stage of Hepatocellular Carcinoma, Hepatocellular Carcinoma
CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab
The purpose of this study is to determine the safety and efficacy of immunotherapy durvalumab and tremelimumab combined with DEB-TACE in patients with Hepatocellular Carcinoma.
- Trial name
- NCT03638141
- Testing
- Durvalumab, Tremelimumab
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Type 1 Diabetes Mellitus
Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus
The purpose of this study is to determine whether treatment with CTLA4-Ig (Abatacept) in individuals with new onset T1DM will improve insulin secretion (C-peptide production) compared to placebo.
- Trial name
- TN09 (NCT00505375)
- Testing
- CTLA-4 Ig
- Where
- 13 sites in United States, Canada
- Volunteers
- 112 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)